The US Food and Drug Administration recently issued guidance on integrating data-gathering digital health technologies into clinical trials, with the impetus being that wearables, environmental sensors and software applications provide a more objective and efficient way to collect information than traditional data-gathering approaches.
And as many pharma executives recently told In Vivo’s sister publication Scrip, they expect proliferation of digital and decentralized clinical trial components, not least